SecuritySTAF / Staffing 360 Solutions, Inc. (852387208)
CEO and PresidentBriand Matthew James
IndustryHelp Supply Services
Institutional Owners1
Institutional Shares86,165 - 1.83%
Common Shares Outstanding4,720,377 shares (as of 2018-06-30)
Institutional Value$ 65,000 USD

Institutional Stock Ownership and Shareholders

Staffing 360 Solutions, Inc. (NASDAQ:STAF) has 1 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 86,165 shares. Largest shareholders include First Financial Equity Corporation.
Staffing 360 Solutions, Inc. (NASDAQ:STAF) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2017-05-16 13F-HR FIRST FINANCIAL EQUITY CORPORATION 86,165 65

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Staffing 360 Solutions Acquires Key Resources For Carolinas Staffing

2018-09-06 seekingalpha
STAF is continuing to acquire businesses as it pursues $500 million in annual revenues, but management is unable to turn a profit. (1-0)

Staffing 360 Solutions, Inc. 2018 Q2 - Results - Earnings Call Slides

2018-08-16 seekingalpha
The following slide deck was published by Staffing 360 Solutions, Inc. in conjunction with their 2018 Q2 earnings call. (1-1)

Staffing 360 Solutions, Inc. (STAF) CEO Brendan Flood on Q2 2018 Results - Earnings Call Transcript

2018-08-15 seekingalpha
Staffing 360 Solutions, Inc. (NASDAQ:STAF) Q2 2018 Earnings Conference Call August 15, 2018 9:00 AM ET (5-1)

Staffing 360 Solutions Could Be Acquiring Its Way Out Of Debt

2018-07-11 seekingalpha
The shares of Staffing 360 Solutions increased four-fold in a single day, on what seems to be fairly mundane acquisition news. (1-1)

Staffing 360 Solutions' (STAF) CEO Brendan Flood on Q4 2017 Results - Earnings Call Transcript

2018-04-02 seekingalpha
Staffing 360 Solutions, Inc. (NASDAQ:STAF) Q4 2017 Earnings Conference Call April 2, 2018 10:00 AM ET (32-1)

CUSIP: 852387208